Received Dec 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (IMOVAX) | SANOFI PASTEUR | UNK | — | OT |
was exposed on 04-Dec-2025. however imovax was administered on 09-dec-2025 with no reported adverse event; Initial information received on 09-Dec-2025 regarding an unsolicited valid non-serious case received from a physician. This case involves a patient with unknown age and gender who was exposed on 04-dec-2025, however Rabies (Hdc) Vaccine [Imovax Rabies] was administered on 09-dec-2025 with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 09-Dec-2025, the patient received an unknown dose of suspect Rabies (Hdc) Vaccine, Powder and solvent for suspension for injection (lot number, expiry date and strength not reported) via unknown route in unknown administration site for prophylactic vaccination (Immunisation) and was exposed on 04-dec-2025. however was administered on 09-dec-2025 with no reported adverse event (inappropriate schedule of product administration) (latency same day). It was reported "If there was a significant delay in beginning post-exposure prophylaxis, was the spacing of doses still the same beginning from the first day of administration (day 0). And was it still 5 doses that is recommended? For the immunoglobulin, was there a timeline on when to give the first dose of Immunoglobulin if there was a delay after exposure? She was asking for a patient who was exposed on 04-Dec-2025. If Imovax Rabies is started today, 09Dec2025, does the spacing of doses remain the same and also for 5 total doses". Action taken was not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.